Related Experiment Videos

Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer

R Rosso¹, A Alama, L Repetto

¹Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Cancer Chemotherapy and Pharmacology

|January 1, 1990

Abstract:

A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cancers.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)].

Cancer treatment reviews·2025

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.

Cancer treatment reviews·2023

Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.

ESMO open·2022

See all related articles